DUBLIN--(BUSINESS WIRE)--The "Global Veterinary Clostridium Vaccine Market 2017-2021" report has been added to Research and Markets' offering.
The global veterinary clostridium vaccine market to grow at a CAGR of 4.96% during the period 2017-2021.
The report, Global Veterinary Clostridium Vaccine Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
According to the report, one driver in the market is advances in technology. The advances in technology have improved the overall pharmacokinetics and dynamics of vaccines along with cost-effective processes. The use of cell line culture in manufacturing viral vaccinations has been increased, which improved the quality of vaccinations. For instance, Valneva SE developed EB66 cell line, which can be used for high-efficiency vaccine production. This cell line is derived from stem cells of duck embryo. This can be used for large-scale manufacturing of veterinary vaccines.
Key vendors
- Elanco
- Merck
- Merial
-
Zoetis
Other prominent vendors
- Advaxis
- AMPLIPHI
- Aratana Therapeutics
- ARKO Labs
- Bayer
- CanFel Therapeutics
- Ceva
- Colorado Serum Company
- Epitopix
- Genus
- Hygieia Biological Laboratories
- NEXVET
- Nuovo Biologics
- Valneva SE
- Vetoquinol
-
Virbac
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: An overview of Clostridial Disease
PART 06: Market landscape
PART 07: Market segmentation by species type
PART 08: Geographical segmentation
PART 09: Decision framework
PART 10: Drivers and challenges
PART 11: Market trends
PART 12: Vendor landscape
PART 13: Key vendor analysis
PART 14: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/gfbq4t/global_veterinary
